drugset
drugset / Trial / NCT00561067

Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)

NCT00561067 ↗

Phase 3 Terminated 10 enrolled Niguarda Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the tolerability and efficacy of erythropoietin (EPO) treatment in spinal shock in comparison with the methylprednisolone treatment (MP).

Timeline

Start
2008-04
Primary completion
2008-07
Completion
2008-07

Outcome

Outcome not reported

Stopped: “Italian Medicines Agency decision”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 5.4 mg/kg Intravenous
Subject epoetin alfa Protein / enzyme biologic 500 iu/kg Intravenous

Indications

spinal cord injury